<DOC>
	<DOCNO>NCT00396227</DOCNO>
	<brief_summary>This study design evaluate , primary care setting , safety efficacy vildaglipgtin add therapy metformin relative TZD add metformin patient type 2 diabetes inadequately control metformin alone .</brief_summary>
	<brief_title>Safety Efficacy Vildagliptin vs. Thiazolidinedione add-on Therapy Metformin Patients With Type 2 Diabetes Not Controlled With Metformin Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients receive stable dose metformin consist least 1,000 mg/day four week prior Visit 1 ( week2 ) Agreement maintain dose metformin screen end study Age range 1880 year Body mass index ( BMI ) range 2240 kg/m2 HbA1c range 7.0 10 % FPG &lt; 270 mg/dL ( 15 mmol/L ) A history type 1 diabetes Liver disease Treatment insulin oral antidiabetic metformin , within 8 week prior Visit 1 Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>hemoglobin A1c</keyword>
	<keyword>metformin</keyword>
</DOC>